Abstract 44P
Background
Circulating tumor cells (CTC) detection has proven to be an important parameter for predicting progression-free and overall survival. CTCs provide a so-called real-time liquid biopsy which gives better opportunities for selection of treatment.
Methods
A prospective observational study conducted the Rajiv Gandhi Cancer Institute & Research Centre, New Delhi. 36 treatment naïve patients of metastatic breast cancer were enrolled from April 2016 and May 2018. CTCs were detected using Cellsearch system. Correlation of CTCs with patient’s outcome after chemotherapy in terms of progression-free survival (PFS) and overall survival (OS) were calculated at one year. The level of CTCs in peripheral blood was measured at baseline before chemotherapy and then at 1 month and 6 months of treatment. All patients underwent PET-CT scan at 3 months and 6 months of treatment.
Results
36 patients were included in this study. The mean CTCs at baseline was 13.8 (0-48), with 75% of patients having CTC ≥5. A positive correlation with the number of sites of metastasis with the number of CTCs was noted (p < 0.001 and R = 0.886). Around 11% of the patients had a complete response (CR) after 3 months of therapy as determined by imaging with a mean number of CTCs 21 (median 17) before starting the treatment and 4.25 (median 4.5) at 1 month (P = 0.14). Similarly, partial response at 3 months, the mean CTCs significantly decreased to 6.3 from 12.9 (p = 0.001). Patients with baseline CTCs<5 had a mean PFS of 9.8 months (95% CI of 7.2 to 12.3) and patients with baseline CTCs ≥5 had a mean PFS of 8.6 months (95% CI of 7.1 to 10.1) (p = 0.37). Patients with CTCs < 5 after one month of treatment had a mean OS of 11.6 months (95% CI of 10.8 to 12.4) and patients with CTCs≥5 after one of treatment had a mean overall survival of 9.6 months (95% CI of 8.0 to 11.2) (p = 0.08).
Conclusions
Our results have implications for both standard care and clinical research in developing countries. More accurate determination of treatment effectiveness early in the course of therapy might spare patient therapy-related toxicity from futile therapy, patient families from financial toxicity and allow treatment to be changed to a more effective regimen.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rajiv Gandhi Cancer Institute and Research Centre, New Delhi.
Funding
Rajiv Gandhi Cancer Institute and Research Centre, New Delhi.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract